For the quarter ending 2025-09-30, TBPH had -$107,154K decrease in cash & cash equivalents over the period. -$6,508K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | 3,615 | 41,256 |
| Depreciation and amortization | 405 | 822 |
| Amortization and accretion on investment securities, net | 771 | 749 |
| Future royalty payment contingency interest accretion | 573 | 1,306 |
| Share-based compensation | 4,576 | 9,420 |
| Loss on disposal of property and equipment | 0 | -35 |
| Amortization of right-of-use assets | 1,002 | 1,906 |
| Deferred income taxes | 994 | -12,543 |
| Other | 22 | 73 |
| Receivables from collaborative and licensing arrangements | -3,652 | 3,479 |
| Receivables from milestones and royalty assets | 0 | -50,000 |
| Prepaid clinical and development services | 0 | -73 |
| Other prepaid and current assets | 1,179 | 1,367 |
| Right-of-use lease assets | -41 | 45 |
| Future contingent milestone and royalty assets | 0 | -144,200 |
| Other assets | 413 | 915 |
| Accounts payable | 538 | -567 |
| Accrued personnel-related expenses, accrued clinical and development expenses, and other accrued liabilities | 3,606 | 1,678 |
| Operating lease liabilities | -1,862 | -3,363 |
| Unrecognized tax benefits | 1,360 | 2,606 |
| Income tax payable | -22,622 | 20,843 |
| Other long-term liabilities | -1 | 69 |
| Net cash provided by (used in) operating activities | -6,508 | 251,113 |
| Purchases of property and equipment | 0 | 34 |
| Purchases of marketable securities | 124,746 | 58,542 |
| Maturities of marketable securities | 24,500 | 52,950 |
| Net cash used in investing activities | -100,246 | -5,626 |
| Proceeds from the sale of ordinary shares | 0 | 20 |
| Proceeds from option exercises | 278 | - |
| Repurchase of shares to satisfy tax withholding | 678 | 1,377 |
| Net cash used in financing activities | -400 | -1,357 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | -107,154 | 244,130 |
| Cash and cash equivalents at beginning of period | 38,633 | - |
| Cash and cash equivalents at end of period | 175,609 | - |
Theravance Biopharma, Inc. (TBPH)
Theravance Biopharma, Inc. (TBPH)